This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/12/2548    most recent ATVBAHA.107.148551v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nangaku, M. Articles by Miyata, T. Search for Related Content PubMed PubMed Citation Articles by Nangaku, M. Articles by Miyata, T. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2548.)
© 2007 American Heart Association, Inc.

Vascular Biology

A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia

Masaomi Nangaku; Yuko Izuhara; Shunya Takizawa; Toshiharu Yamashita; Yoshiaki Fujii-Kuriyama; Osamu Ohneda; Masayuki Yamamoto; Charles van Ypersele de Strihou; Noriaki Hirayama; Toshio Miyata

From the Division of Nephrology and Endocrinology (M.N.), University of Tokyo School of Medicine, Japan; the Institute of Medical Sciences (Y.I., S.T., T.M.), Divisions of Nephrology, Hypertension, and Metabolism and of Neurology, Tokai University School of Medicine, Kanagawa, Japan; the Center for Tsukuba Advanced Research Alliance and Institute of Basic Medical Sciences (T.Y., O.O.), University of Tsukuba, Japan; the Center for Tsukuba Advanced Research Alliance (Y.F.-K.), University of Tsukuba, Japan; the Center for Tsukuba Advanced Research Alliance and JST-ERATO Environmental Response Project (M.Y.), University of Tsukuba, and the Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan; the Service de Nephrologie (C.v.Y.d.S.), Universite Catholique de Louvain, Brussels, Belgium; and the Basic Medical Science and Molecular Medicine (N.H.), Tokai University School of Medicine, Kanagawa, Japan.

Correspondence to Toshio Miyata, MD, PhD, Institute of Medical Sciences and Division of Nephrology, Hypertension and Metabolism, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan. E-mail t-miyata{at}is.icc.u-tokai.ac.jp

Objective— Hypoxia inducible factor (HIF) plays a pivotal role in the adaptation to ischemic conditions. Its activity is modulated by an oxygen-dependent hydroxylation of proline residues by prolyl hydroxylases (PHD).

Methods and Results— We discovered 2 unique compounds (TM6008 and TM6089), which inhibited PHD and stabilized HIF activity in vitro. Our docking simulation studies based on the 3-dimensional structure of human PHD2 disclosed that they preferentially bind to the active site of PHD. Whereas PHD inhibitors previously reported inhibit PHD activity via iron chelation, TM6089 does not share an iron chelating motif and is devoid of iron chelating activity. In vitro Matrigel assays and in vivo sponge assays demonstrated enhancement of angiogenesis by local administration of TM6008 and TM6089. Their oral administration stimulated HIF activity in various organs of transgenic rats expressing a hypoxia-responsive reporter vector. No acute toxicity was observed up to 2 weeks after a single oral dose of 2000 mg/kg for TM6008. Oral administration of TM6008 protected neurons in a model of cerebrovascular disease. The protection was associated with amelioration of apoptosis but independent of enhanced angiogenesis.

Conclusions— The present study uncovered beneficial effects of novel PHD inhibitors preferentially binding to the active site of PHD.

We discovered 2 compounds (TM6008 and TM6089) that inhibited PHD and stabilized HIF activity. Local administration of TM6008 and TM6089 enhanced angiogenesis, and their oral administration stimulated HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector. Oral administration of TM6008 protected neurons in a model of ischemic cerebrovascular disease.

Key Words: hypoxia • hypoxia inducible factor • structure based drug design • stroke • ischemia

This article has been cited by other articles:

				K. Takeda, T. Ichiki, E. Narabayashi, K. Inanaga, R. Miyazaki, T. Hashimoto, H. Matsuura, J. Ikeda, T. Miyata, and K. Sunagawa Inhibition of Prolyl Hydroxylase Domain-Containing Protein Suppressed Lipopolysaccharide-Induced TNF-{alpha} Expression Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2132 - 2137. [Abstract] [Full Text] [PDF]

				K. Schultz, V. Murthy, J. B. Tatro, and D. Beasley Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1{alpha}-dependent mechanisms Am J Physiol Lung Cell Mol Physiol, June 1, 2009; 296(6): L921 - L927. [Abstract] [Full Text] [PDF]

				T. Miyata and C. van Ypersele de Strihou Translation of basic science into clinical medicine: novel targets for diabetic nephropathy Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1373 - 1377. [Full Text] [PDF]